Shots:

• The P-ll CodeBreaK 100 study involves assessing of Sotorasib (proposed INN for AMG 510- 960mg) in 126 patients with KRAS G12C-mutant advanced NSCLC- whose cancer had progressed despite prior treatment with CT and/or immunotherapy
• Result: ORR is consistent with previously reported P-I study while other measures of efficacy including DoR are promising and 50%+ of the responders were still on treatment and continuing to respond as of the data cutoff date whereas safety & tolerability is similar to previous P-I data
• Detailed results of the P-II study will be submitted to the IASLC 2020 World Congress on Lung Cancer while the company has begun recruiting in P-III CodeBreaK 200 study evaluating Sotorasib vs docetaxel  in KRAS G12C-mutant NSCLC patients

­ Ref: Amgen | Image: Reuters